June 10, 2019 08:03 AM EDTUpdated July 3, 10:25 AM
Deals

Mer­ck makes a $773M bet on TGFβ, ac­quir­ing a three-year-old biotech

Natalie Grover

Reporter

When check­point in­hibitors work, they can per­form won­ders. But for many can­cer pa­tients, in-built or ac­quired re­sis­tance to these im­munother­a­pies im­pedes their ef­fi­ca­cy. Mer­ck, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times